NCT04249167 is a phase I trial study examining the side effects and feasibility of cryoablation, Atezolizumab (anti-PD-L1) and Nab-paclitaxel [solvent free, albumin bound nanoparticle formation of paclitaxel which promotes assembly of tubulin into microtubules and prevents their dissociation resulting in the blockage of cell cycle progression and inhibiting the growth of cancer cells (21)] in treating patients with triple negative breast cancer that has spread to nearby tissue or lymph nodes or has spread to other sites within the body. Here, CD274 is linked to cancer.